Get the Stockscreener App
5.27
0.10%
0.07
Opus Genetics Inc stock is traded at $5.27, with a volume of 140.59K.
It is up +0.10% in the last 24 hours and up +12.91% over the past month.
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes seven adeno-associated virus (AAV)-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RHO, CNGB1, RDH12, NMNAT1, and MERTK. The company operates in one operating segment, which is the business of developing products related to vision performance and health.
See More
Previous Close:
$5.20
Open:
$5.21
24h Volume:
140.59K
Relative Volume:
0.15
Market Cap:
$375.58M
Revenue:
$14.20M
Net Income/Loss:
$-49.59M
P/E Ratio:
-6.2559
EPS:
-0.8424
Net Cash Flow:
$-35.25M
1W Performance:
+11.46%
1M Performance:
+12.91%
6M Performance:
+156.40%
1Y Performance:
+458.42%
1-Day Range:
$5.03
$5.27
1-Week Range:
$4.70
$5.40
52-Week Range:
$0.9011
$5.81
Opus Genetics Inc Stock (IRD) Company Profile
Name
Opus Genetics Inc
Sector
Industry
Phone
248-681-9815
Address
8 DAVIS DRIVE, DURHAM
Compare IRD vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IRD
Opus Genetics Inc
|
5.26 | 371.29M | 14.20M | -49.59M | -35.25M | -0.8424 |
VRTX
Vertex Pharmaceuticals Inc
|
428.25 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
720.03 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
811.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
304.18 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
315.00 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Opus Genetics Inc Stock (IRD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-30-26 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-16-26 | Initiated | Oppenheimer | Outperform |
| Jan-20-26 | Initiated | BTIG Research | Buy |
| Dec-10-25 | Initiated | B. Riley Securities | Buy |
| Nov-25-25 | Initiated | Piper Sandler | Overweight |
| Oct-29-25 | Initiated | Wedbush | Outperform |
| Oct-16-25 | Initiated | Chardan Capital Markets | Buy |
| Apr-11-25 | Initiated | Craig Hallum | Buy |
| Nov-13-24 | Resumed | H.C. Wainwright | Buy |
View All
Opus Genetics Inc Stock (IRD) Latest News
Here is Why Opus Genetics (IRD) is One of the Best Performing NASDAQ Stocks - Yahoo Finance
Citizens reiterates Opus Genetics stock rating on FDA program acceptance - Investing.com UK
Citizens reiterates Opus Genetics stock rating on FDA program acceptance By Investing.com - Investing.com Australia
Opus Genetics’ LCA5 gene therapy accepted into FDA program - Investing.com
FDA rare-disease program takes in Opus therapy for childhood blindness - Stock Titan
Opus Genetics Announces FDA Acceptance of OPGx-LCA5 into Rare Disease Evidence Principles (RDEP) Program - GlobeNewswire
Citizens reiterates Opus Genetics stock rating on gene therapy data By Investing.com - Investing.com Australia
Citizens reiterates Opus Genetics stock rating on gene therapy data - Investing.com
Citizens Initiates Coverage on Opus Genetics with Outperform Rating - HarianBasis.co
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Opus Genetics (IRD), NeoGenomics (NEO) and Teladoc (TDOC) - The Globe and Mail
Citizens Initiates Coverage of Opus Genetics (IRD) - Insider Monkey
IRD Stock Price, Quote & Chart | OPUS GENETICS INC (NASDAQ:IRD) - ChartMill
B. Riley Securities Maintains Opus Genetics(IRD.US) With Buy Rating, Raises Target Price to $10 - Moomoo
B. Riley Adjusts Opus Genetics Price Target to $10 From $9, Maintains Buy Rating - marketscreener.com
Opus Genetics to Participate in Leading Medical Conferences in May 2026 - Sahm
IRD Initiated Coverage by Citizens -- Rating Set to Market Outpe - GuruFocus
Opus Genetics higher after $25M private placement - MSN
Citizens JMP Initiates Opus Genetics(IRD.US) With Buy Rating, Announces Target Price $12 - Moomoo
Opus Genetics (NASDAQ:IRD) Now Covered by Analysts at Citizens Jmp - MarketBeat
Citizens initiates Opus Genetics stock coverage with outperform rating - Investing.com UK
Citizens initiates Opus Genetics stock coverage with outperform rating By Investing.com - Investing.com Australia
Citizens Initiates Coverage of Opus Genetics (IRD) with Market Outperform Recommendation - MSN
Opus Genetics (NASDAQ:IRD) CFO Robert Gagnon Sells 7,842 Shares - MarketBeat
Opus Genetics (NASDAQ:IRD) CEO Sells $49,647.42 in Stock - MarketBeat
Opus Genetics president Benjamin Yerxa sells $39,121 in stock By Investing.com - Investing.com Australia
Opus Genetics president Benjamin Yerxa sells $39,121 in stock - Investing.com
Opus Genetics CEO George Magrath sells $49,647 in stock By Investing.com - Investing.com Australia
[Form 4] Opus Genetics, Inc. Insider Trading Activity - Stock Titan
Opus Genetics CSO Jayagopal Ashwath sells $39,155 in stock By Investing.com - Investing.com South Africa
Opus Genetics CEO George Magrath sells $49,647 in stock - Investing.com UK
Opus Genetics CSO Jayagopal Ashwath sells $39,155 in stock - Investing.com
Opus Genetics (IRD) COO sells shares to cover tax withholding - Stock Titan
Small Opus Genetics (IRD) insider sale made to cover RSU taxes - Stock Titan
Opus Genetics (IRD) CEO sells 9,511 shares to cover tax withholding - Stock Titan
Opus Genetics (IRD) officer auto-sells 7,542 shares for RSU taxes - Stock Titan
Opus Genetics (IRD) CFO has 7,842 shares sold to cover RSU taxes - Stock Titan
Opus Genetics (IRD) price target increased by 23.44% to 9.73 - MSN
Opus Genetics secures up to $155M financing from Oberland Capital - MSN
Opus Genetics, Inc. Files Form 8-K: Company Information, Address, and NASDAQ Listing Details - Minichart
Opus Genetics issues $35 million in senior secured notes under new agreement By Investing.com - Investing.com South Africa
Opus Genetics issues $35 million in senior secured notes under new agreement - Investing.com UK
Opus Genetics Inc Stock (IRD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.78%
3.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):